STOCK TITAN

Apellis and Sobi Announce Positive Topline Results from Phase 3 VALIANT Study of Pegcetacoplan in C3G and Primary IC-MPGN

Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Neutral)

Apellis Pharmaceuticals (Nasdaq: APLS) and Sobi announced positive topline results from the Phase 3 VALIANT study of pegcetacoplan in C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN). The study met its primary endpoint, showing a statistically significant 68% reduction in proteinuria compared to placebo at Week 26. Results were consistent across all subgroups, including C3G and IC-MPGN, adolescent and adult patients, and native and post-transplant kidneys.

Pegcetacoplan also demonstrated significance on key secondary endpoints and favorable safety. Apellis plans to submit a supplemental new drug application to the FDA in early 2025, while Sobi plans to submit a marketing application with the EMA in 2025.

Apellis Pharmaceuticals (Nasdaq: APLS) e Sobi hanno annunciato risultati preliminari positivi dallo studio di Fase 3 VALIANT riguardante il pegcetacoplan nella glomerulopatia da C3 (C3G) e nella glomerulonefrite membranoproliferativa primaria a complessi immuni (IC-MPGN). Lo studio ha raggiunto il suo obiettivo primario, dimostrando una riduzione statisticamente significativa del 68% nella proteinuria rispetto al placebo alla settimana 26. I risultati sono stati coerenti in tutti i sottogruppi, inclusi C3G e IC-MPGN, pazienti adolescenti e adulti, e in reni nativi e post-trapianto.

Il pegcetacoplan ha anche mostrato significatività su endpoint secondari chiave e sicurezza favorevole. Apellis prevede di presentare una domanda supplementare per un nuovo farmaco alla FDA all'inizio del 2025, mentre Sobi prevede di presentare una domanda di commercializzazione presso l'EMA nel 2025.

Apellis Pharmaceuticals (Nasdaq: APLS) y Sobi anunciaron resultados preliminares positivos del estudio de Fase 3 VALIANT sobre pegcetacoplan en la glomerulopatía por C3 (C3G) y la glomerulonefritis membranoproliferativa inmunitaria primaria (IC-MPGN). El estudio cumplió su objetivo principal, mostrando una reducción estadísticamente significativa del 68% en la proteinuria en comparación con el placebo en la semana 26. Los resultados fueron consistentes en todos los subgrupos, incluidos C3G e IC-MPGN, pacientes adolescentes y adultos, así como riñones nativos y post-transplante.

El pegcetacoplan también demostró significancia en los endpoints secundarios clave y presentó una seguridad favorable. Apellis planea presentar una solicitud suplementaria de nuevo fármaco a la FDA a principios de 2025, mientras que Sobi planea presentar una solicitud de comercialización a la EMA en 2025.

Apellis Pharmaceuticals (Nasdaq: APLS)와 Sobi는 pegcetacoplan이 C3 사구체병(C3G) 및 1차 면역복합체 증식성 사구체 신염(IC-MPGN)에 대해 진행한 3상 VALIANT 연구에서 긍정적인 주요 결과를 발표했습니다. 이 연구는 주요 목표를 달성했으며, 26주 차에 위약과 비교해 단백뇨가 통계적으로 유의미한 68% 감소를 보였습니다. 결과는 C3G 및 IC-MPGN, 청소년 및 성인 환자, 본래 신장 및 이식 후 신장 등 모든 하위 그룹에서 일관되었습니다.

Pegcetacoplan은 주요 2차 목표에서도 유의미성을 보였으며, 안전성 또한 긍정적이었습니다. Apellis는 2025년 초에 FDA에 보완 신약 신청서를 제출할 계획이며, Sobi는 2025년에 EMA에 마케팅 신청서를 제출할 계획입니다.

Apellis Pharmaceuticals (Nasdaq: APLS) et Sobi ont annoncé des résultats préliminaires positifs de l'étude de Phase 3 VALIANT concernant le pegcetacoplan dans la glomerulopathie à C3 (C3G) et la glomerulonéphrite membranoproliferative immunitaire primaire (IC-MPGN). L'étude a atteint son objectif principal, montrant une réduction statistiquement significative de 68% de la protéinurie par rapport au placebo à la semaine 26. Les résultats étaient cohérents dans tous les sous-groupes, y compris C3G et IC-MPGN, patients adolescents et adultes, ainsi que les reins natifs et post-transplantation.

Le pegcetacoplan a également montré une signification sur les principaux critères secondaires et une sécurité favorable. Apellis envisage de soumettre une demande de médicament complémentaire à la FDA début 2025, tandis que Sobi prévoit de soumettre une demande de commercialisation à l'EMA en 2025.

Apellis Pharmaceuticals (Nasdaq: APLS) und Sobi haben positive vorläufige Ergebnisse aus der Phase-3-Studie VALIANT zu Pegcetacoplan bei C3-Glomerulopathie (C3G) und primärer immuner membranproliferativer Glomerulonephritis (IC-MPGN) bekannt gegeben. Die Studie hat ihren primären Endpunkt erreicht und zeigte eine statistisch signifikante Reduktion der Proteinurie um 68% im Vergleich zur Placebo-Gruppe nach 26 Wochen. Die Ergebnisse waren in allen Subgruppen konsistent, einschließlich C3G und IC-MPGN, jugendlichen und erwachsenen Patienten sowie in einheimischen und post-transplantierten Nieren.

Pegcetacoplan zeigte auch eine signifikante Verbesserung der wichtigsten sekundären Endpunkte und eine günstige Sicherheitsbewertung. Apellis plant, Anfang 2025 einen ergänzenden New-Drug-Antrag bei der FDA einzureichen, während Sobi plant, 2025 einen Antrag auf Marktzulassung bei der EMA zu stellen.

Positive
  • Met primary endpoint with 68% reduction in proteinuria (p<0.0001)
  • Positive results consistent across all subgroups
  • Demonstrated statistical significance on key secondary endpoints
  • Favorable safety profile consistent with established data
  • Plans for regulatory submissions in US and EU in 2025
Negative
  • None.

The VALIANT study results for pegcetacoplan in C3G and IC-MPGN are highly significant. The 68% reduction in proteinuria (p<0.0001) is clinically meaningful and consistent across subgroups. This is a major breakthrough for these rare kidney diseases with no approved treatments.

Key points:

  • Met primary endpoint and key secondary endpoints
  • Positive results in both native and transplanted kidneys
  • Favorable safety profile
  • Potential to delay or prevent kidney failure

These results position pegcetacoplan as a first-in-class therapy for C3G and IC-MPGN, potentially transforming patient outcomes. The consistency across subgroups suggests broad applicability, which is important for rare diseases.

This is a significant win for Apellis and Sobi. The strong VALIANT results in C3G and IC-MPGN expand pegcetacoplan's potential market beyond its current PNH approval. Key implications:

  • Likely regulatory approval in US and EU, given robust efficacy and safety data
  • Potential for orphan drug designation, providing market exclusivity
  • First-mover advantage in an untapped rare disease market
  • Strengthens pegcetacoplan's position as a platform therapy for complement-mediated diseases

The planned regulatory submissions in early 2025 suggest a potential launch in 2026. This timeline gives Apellis and Sobi a significant lead in this indication, potentially establishing pegcetacoplan as the standard of care for C3G and IC-MPGN.

The positive VALIANT results are a major catalyst for Apellis (NASDAQ: APLS) and Sobi (STO: SOBI). This expands pegcetacoplan's market potential significantly:

  • C3G and IC-MPGN represent a new revenue stream
  • Orphan indication suggests high pricing potential
  • Broadens pegcetacoplan's utility, potentially increasing investor confidence
  • Could drive upward revisions in peak sales estimates

While market size is due to disease rarity, the unmet need and lack of competition suggest strong uptake upon approval. This news likely strengthens Apellis' position and could attract increased investor interest in both Apellis and Sobi. Watch for potential analyst upgrades and increased institutional interest in the coming weeks.

  • Met the primary endpoint, achieving statistically significant 68% (p<0.0001) reduction in proteinuria compared to placebo in a broad study population
  • Positive results consistent across all subgroups, including C3G and IC-MPGN, adolescent and adult patients, and native and post-transplant kidneys
  • Demonstrated favorable safety, consistent with established profile
  • Companies plan to submit data for regulatory approval in the US and EU
  • Apellis to host a conference call today at 8:00 a.m. ET

WALTHAM, Mass. and STOCKHOLM, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) and Sobi® (STO: SOBI) today announced positive topline results from the Phase 3 VALIANT study investigating systemic pegcetacoplan in patients with C3 glomerulopathy (C3G) or primary immune complex membranoproliferative glomerulonephritis (IC-MPGN), which are rare kidney diseases with no approved treatments.

The study met the primary endpoint, demonstrating a statistically significant and clinically meaningful 68% (p<0.0001) proteinuria reduction (log-transformed ratio of urine protein-to-creatinine ratio) in C3G and IC-MPGN patients treated with pegcetacoplan compared to placebo, both in addition to background therapy, at Week 26. Results were consistent across all subgroups, including C3G and IC-MPGN, adolescent and adult patients, and native and post-transplant kidneys.

Pegcetacoplan also demonstrated statistical significance on the key secondary endpoints of composite renal endpoint, which combines proteinuria reduction and estimated glomerular filtration rate (eGFR) stabilization, and proteinuria reduction of at least 50% compared to baseline, as well as nominal significance on the histological endpoint of reduction in C3c staining on kidney biopsy and stabilization of kidney function as measured by eGFR compared to placebo.

“As a clinician, I’m thrilled by these groundbreaking results, which show that pegcetacoplan has the potential to significantly improve the lives of patients with C3G and IC-MPGN, regardless of disease type, age, and transplant status,” said Carla Nester, M.D. MSA, FASN, lead principal investigator for the VALIANT study and Jean E. Robillard M.D., professor of pediatric nephrology, University of Iowa Stead Family Children's Hospital. “Currently, many patients living with these rare diseases will eventually require a kidney transplant or lifelong dialysis, so there is an urgent need for a treatment that targets the underlying cause of these diseases. These positive data are a major advance for the rare kidney disease community.”

“These results exceeded our already high expectations. Pegcetacoplan is the first investigational therapy to show such a strong reduction in proteinuria in C3G and IC-MPGN with supportive data across multiple measures of disease activity,” said Jeffrey Eisele, Ph.D., chief development officer, Apellis. “Building on pegcetacoplan’s approval in PNH, we look forward to sharing these data with the FDA and working quickly to bring this treatment to patients with these debilitating kidney diseases.”

"Today’s announcement further strengthens our belief in pegcetacoplan’s potential to meet the critical needs of patients with these severe and life-threatening kidney conditions," stated Lydia Abad-Franch, M.D., head of R&D, medical affairs, and chief medical officer, Sobi. "We remain committed to progressing pegcetacoplan's development and expanding its reach, driven by our steadfast mission to transform the lives of those affected by rare diseases."

In the VALIANT study, pegcetacoplan demonstrated favorable safety and tolerability, consistent with its established profile. Rates of adverse events (AEs), serious AEs, and AEs leading to study drug discontinuation were similar between the pegcetacoplan and placebo groups. There were no cases of meningitis or serious infections attributed to encapsulated bacteria.

All patients who have already completed the VALIANT study have now enrolled into the VALE long-term extension study.

Apellis plans to submit a supplemental new drug application to the U.S. Food and Drug Administration in early 2025. Sobi also plans to submit a marketing application with the European Medicines Agency in 2025. Detailed data will be presented at an upcoming medical congress.

Conference Call and Webcast
Apellis will host a conference call and webcast with Andrew Bomback, M.D., principal investigator for the VALIANT study and director of clinical research, division of nephrology at Columbia University Medical Center​ to discuss the Phase 3 VALIANT results on Thursday, August 8 at 8:00 a.m. ET. To access the live call by phone, please dial (877) 550-1707 (U.S.) or (848) 488-9020 (International) and reference “Apellis Pharmaceuticals”. A live audio webcast of the event may also be accessed through the “Events and Presentations” page of the “Investors and Media” section of the company’s website. A replay of the webcast will be available for 30 days following the event.

About the VALIANT Study
The VALIANT Phase 3 study (NCT05067127) is a randomized, placebo-controlled, double-blinded, multi-center study designed to evaluate pegcetacoplan efficacy and safety in 124 patients who are 12 years of age and older with C3G or primary IC-MPGN. It is the largest single trial conducted in these populations and the only study to include adolescent and adult patients, with native and post-transplant kidneys. Study participants were randomized to receive 1080 mg of pegcetacoplan or placebo twice weekly for 26 weeks. Following this 26-week randomized controlled period, patients are able to proceed to a 26-week open-label phase in which all patients receive pegcetacoplan. The primary endpoint of the study was the log transformed ratio of urine protein-to-creatinine ratio (uPCR) at Week 26 compared to baseline.

About C3 Glomerulopathy (C3G) and Primary Immune-Complex Membranoproliferative Glomerulonephritis (IC-MPGN)
C3G and primary IC-MPGN are rare and debilitating kidney diseases that can lead to kidney failure. Excessive C3c deposits are a marker of disease activity, which can lead to kidney inflammation, damage, and failure. There are no treatments that target the underlying cause of these diseases. Approximately 50% of people living with C3G and IC-MPGN suffer from kidney failure within five to 10 years of diagnosis, requiring a burdensome kidney transplant or lifelong dialysis.1 Additionally, two-thirds of patients who previously received a kidney transplant will experience disease recurrence.2 The diseases are estimated to affect 5,000 people in the United States and up to 8,000 in Europe.3 

About Pegcetacoplan in Rare Diseases
Pegcetacoplan is a targeted C3 therapy designed to regulate excessive activation of the complement cascade, a part of the body’s immune system, which can lead to the onset and progression of many serious diseases. Pegcetacoplan is under investigation for rare diseases across hematology and nephrology. Pegcetacoplan is approved for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) as EMPAVELI®/Aspaveli® in the United States, European Union, and other countries globally.

About the Apellis and Sobi Collaboration
Apellis and Sobi have global co-development rights for systemic pegcetacoplan. Sobi has exclusive ex-U.S. commercialization rights for systemic pegcetacoplan, and Apellis has exclusive U.S. commercialization rights for systemic pegcetacoplan and worldwide commercial rights for ophthalmological pegcetacoplan, including for geographic atrophy.

About Sobi®
Sobi is a specialized international biopharmaceutical company transforming the lives of people with rare and debilitating diseases. Providing reliable access to innovative medicines in the areas of hematology, immunology, and specialty care. Sobi has approximately 1,800 employees across Europe, North America, the Middle East, Asia, and Australia. In 2023, revenue amounted to SEK 22.1 billion. Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at sobi.com and LinkedIn.

About Apellis
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that combines courageous science and compassion to develop life-changing therapies for some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in 15 years and now have two approved medicines targeting C3. These include the first-ever therapy for geographic atrophy, a leading cause of blindness around the world. We believe we have only begun to unlock the potential of targeting C3 across serious retinal, rare, and neurological diseases. For more information, please visit http://apellis.com or follow us on X (Twitter) and LinkedIn.

Apellis Forward-Looking Statement 
Statements in this press release about future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements” within the meaning of The Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding plans to submit applications for regulatory approval for the treatment of patients with C3G and IC-MPGN. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including whether systemic pegcetacoplan will receive approval for those indications from the FDA or equivalent foreign regulatory agencies when expected or at all; and any other factors discussed in the “Risk Factors” section of Apellis’ Annual Report on Form 10-K with the Securities and Exchange Commission on February 27, 2024 and the risks described in other filings that Apellis may make with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Apellis specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

Media:
Tracy Vineis
media@apellis.com
617.977.6764

Investors: 
Meredith Kaya
meredith.kaya@apellis.com
617.599.8178

References
1. C3 glomerulopathy. National Institute of Health, Genetics Home Reference. https://ghr.nlm.nih.gov/condition/c3-glomerulopathy#resources. Accessed November 21, 2019. 
2. Zand L, et al Clinical findings, pathology, and outcomes of C3GN after kidney transplantation. J Am Soc Nephrol. 2014 May;25(5):1110-7. doi: 10.1681/ASN.2013070715. Epub 2013 Dec 19.
3. Data on file using literature consensus. 


FAQ

What were the main results of the Phase 3 VALIANT study for pegcetacoplan in C3G and IC-MPGN?

The study met its primary endpoint, showing a statistically significant 68% reduction in proteinuria compared to placebo at Week 26. Results were consistent across all subgroups, including C3G and IC-MPGN, adolescent and adult patients, and native and post-transplant kidneys.

When does Apellis (APLS) plan to submit a supplemental new drug application for pegcetacoplan to the FDA?

Apellis plans to submit a supplemental new drug application to the U.S. Food and Drug Administration in early 2025.

What was the safety profile of pegcetacoplan in the VALIANT study?

Pegcetacoplan demonstrated a favorable safety and tolerability profile, consistent with its established profile. Rates of adverse events were similar between the pegcetacoplan and placebo groups, with no cases of meningitis or serious infections attributed to encapsulated bacteria.

How did pegcetacoplan perform on secondary endpoints in the VALIANT study?

Pegcetacoplan demonstrated statistical significance on key secondary endpoints, including the composite renal endpoint (combining proteinuria reduction and eGFR stabilization) and proteinuria reduction of at least 50% compared to baseline.

Apellis Pharmaceuticals, Inc.

NASDAQ:APLS

APLS Rankings

APLS Latest News

APLS Stock Data

4.58B
121.77M
14.28%
97.08%
13.07%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
WALTHAM